Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adaptive Immune System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Adaptive Immune System. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-000116-42 Sponsor Protocol Number: BioVacSafe-QIV Start Date*: 2017-03-02
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus...
    Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003543-35 Sponsor Protocol Number: BioVacSafe–FluadTM Start Date*: 2014-09-23
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad...
    Medical condition: vaccin against influenza
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005860-24 Sponsor Protocol Number: OmniaOMS Start Date*: 2022-10-28
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
    Medical condition: relapsing remitting multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001344-22 Sponsor Protocol Number: 116640 Start Date*: 2013-02-19
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and ...
    Medical condition: Healthy volunteers (Hepatitis B surface antigen (HBsAg) vaccine administered in hepatitis B virus (HBV) naive adult subjects aged between 18 and 45 years old, inclusive, in good general health.)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001304-15 Sponsor Protocol Number: AZGS2021005 Start Date*: 2021-05-06
    Sponsor Name:vzw az groeninge
    Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-...
    Medical condition: immuneresponse after vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002879-14 Sponsor Protocol Number: BioVacSafe-Boostrix® Start Date*: 2015-07-30
    Sponsor Name:Ghent University Hospital
    Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v...
    Medical condition: vaccin against diphtheria, tetanus and pertussis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004526-29 Sponsor Protocol Number: uni-koeln-4602 Start Date*: 2021-10-19
    Sponsor Name:University of Cologne
    Full Title: A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST ...
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    24.0 100000004865 10085559 Revaccination with different COVID-19 vaccine LLT
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.0 100000004865 10084463 SARS-CoV-2 immunisation LLT
    23.0 100000004865 10084466 SARS-CoV-2 immunization LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) IE (Completed) ES (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003759-13 Sponsor Protocol Number: GI1931 Start Date*: 2019-12-20
    Sponsor Name:Department of Oncology, Herlev & Gentofte
    Full Title: Phase 1/2 study in borderline resectable, locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and ...
    Medical condition: Locally advanced pancreatic cancer, non-resectable or borderline resectable, or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004573-32 Sponsor Protocol Number: 21-05 Start Date*: 2021-10-05
    Sponsor Name:Centre Hospitalier Annecy Genevois
    Full Title: Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) versus Standard-Dose (QIV-SD), in subjects 65 years of age and older on innate immunity, including gene expression.
    Medical condition: Healthy volunteers (influenza vaccination)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001982-42 Sponsor Protocol Number: J004 Start Date*: 2012-08-02
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI
    Medical condition: Acute HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10000811 Acute infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001429-33 Sponsor Protocol Number: IM140-103 Start Date*: 2014-11-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP)
    Medical condition: Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001414-10 Sponsor Protocol Number: 202100076 Start Date*: 2021-03-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Vaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002363-22 Sponsor Protocol Number: IIV-482 Start Date*: 2021-05-27
    Sponsor Name:National Institute for Public Health and the Environment
    Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study)
    Medical condition: SARS-CoV-19, frailty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001450-22 Sponsor Protocol Number: MESCEL-COVID19 Start Date*: 2020-04-29
    Sponsor Name:Fundación de Investigación del Hospital Infantil Universitario Niño Jesús
    Full Title: Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19.
    Medical condition: Severe pulmonary involvement by COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004974-16 Sponsor Protocol Number: IL1ra03 Start Date*: 2018-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.
    Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 10029205 - Nervous system disorders 10051288 Central nervous system inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003089-34 Sponsor Protocol Number: HND-IM-011 Start Date*: 2011-09-06
    Sponsor Name:Chr. Hansen A/S
    Full Title: The effect for Lactobacillus paracasei subsp. paracasei, L. casei 431® on immune response to influenza vaccination in healthy adult volunteers - a multi-center, randomized, placebo-controlled, par...
    Medical condition: effect of probiotics on the immune response to seasonal influenza vaccination in healthy adults
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10016794 Flu vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000436-28 Sponsor Protocol Number: Z102-008 Start Date*: 2011-12-07
    Sponsor Name:Zalicus, Inc.
    Full Title: A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI...
    Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000836-24 Sponsor Protocol Number: IIV-406 Start Date*: 2019-06-19
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults.
    Medical condition: Healthy volunteers above 25 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004455-29 Sponsor Protocol Number: 112115 Start Date*: 2008-12-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination wi...
    Medical condition: Hepatitis B surface antigen (HBsAg) vaccine administred in HBV naïve adult subjects aged between 18 and 45 years old, inclusive, in good general health.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 07:31:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA